Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Income Statement [Abstract]
Revenue	$ 26,876	$ 24,109
Cost of revenue	20,545	19,038
Gross profit	6,331	5,071
Operating expenses:
Research and development	2,627	2,596
Selling	1,656	1,632
General and administrative	5,181	5,451
Gain on sales of equipment	(717)
Loss on disposition of Tantaline		162
Impairment charge		111
Total operating expenses, net	8,747	9,952
Operating loss	(2,416)	(4,881)
Other income (expense):
Interest income	559	577
Interest expenses	(19)	(23)
Foreign exchange income		42
Other income	2	91
Total other income, net	542	687
Loss before income tax	(1,874)	(4,194)
Income tax expense (benefit)	24	(14)
Net loss	$ (1,898)	$ (4,180)
Loss per common share:
Basic	$ (0.28)	$ (0.62)
Diluted	$ (0.28)	$ (0.62)
Weighted average number of shares:
Basic	6,823	6,788
Diluted	6,823	6,788